August 2016

Dear shareholders and prospective shareholders,

On August 10th, CRH Medical CEO, Edward Wright presented at the 36th annual Canaccord Genuity Growth Conference in Boston, MA. Institutional investors from around the world were invited to the conference to attend corporate presentations and meet with companies in the growth stage. We continue to pursue opportunities to increase our investor exposure, and the presentation opportunity combined with one-on-one meetings with global institutional investors at the conference, is one of the ways we are broadening our investor audience.

August Marketing

In addition to the marketing that took place in and around the Canaccord Growth Conference, management spent time educating new and existing institutional shareholders both in Canada and the US. We are beginning to see increased inbound interest from US based institutional investors, which was our hope when we listed on the NYSE MKT in September of 2015. Investor outreach on the back of operational execution continues to be the IR strategy on both sides of the border.

GI Conferences

In August, we attended the GI Outlook conference held in Washington, DC. The annual meeting is put on by the American Society for Gastrointestinal Endoscopy and is focused on practice management. Because of this emphasis, the conference is not only attended by physicians, but also by high level practice administrators looking to improve efficiencies and increase practice revenue. The meeting proved quite meaningful for CRH as we generated a solid number of new leads for both sides of the business. After a quiet summer, we are looking forward to September with the conference schedule back in full swing.

If you have any questions regarding news releases you see from CRH, or have anything would like to discuss directly, please don’t hesitate to contact me. Thank you for your continued support and we look forward to updating you again in a month’s time.

David Matousek
Director, Investor Relations
CRH Medical Corporation
T: 800.660.2153 x 1030

We're a stable, profitable company respected by both patients and physicians. Learn more »